Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) — Market Cap & Net Worth
Market Cap & Net Worth: Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) has a market capitalization of $5.96 Billion ($5.96 Billion) as of August 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3227 globally and #1151 in its home market, demonstrating a 3.71% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amneal Pharmaceuticals, Inc. Class A Common Stock's stock price $17.91 by its total outstanding shares 348296027 (348.30 Million). See Amneal Pharmaceuticals, Inc. Class A Com (AMRX) balance sheet quality index to understand what proportion of total assets are financed by equity.
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap History: 2025 to 2026
Amneal Pharmaceuticals, Inc. Class A Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $4.39 Billion to $6.24 Billion (0.00% CAGR). Also see Amneal Pharmaceuticals, Inc. Class A Com assets under control for a full breakdown of the balance sheet.
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Amneal Pharmaceuticals, Inc. Class A Com stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.45x
Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap is 1.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
60.90x
Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap is 60.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $4.39 Billion | $3.02 Billion | $72.06 Million | 1.45x | 60.90x |
Competitor Companies of AMRX by Market Capitalization
Companies near Amneal Pharmaceuticals, Inc. Class A Common Stock in the global market cap rankings as of August 24, 2026. Also see AMRX cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Amneal Pharmaceuticals, Inc. Class A Common Stock by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #552 globally with a market cap of $49.91 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #620 globally with a market cap of $44.56 Billion USD ( CN¥304.53 Billion CNY).
- Haleon plc (NYSE:HLN): Ranked #636 globally with a market cap of $43.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #552 | GALDERMA GROUP AG | NYSE:GALDY | $49.91 Billion | $42.81 |
| #620 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.56 Billion | CN¥47.74 |
| #636 | Haleon plc | NYSE:HLN | $43.73 Billion | $10.00 |
Amneal Pharmaceuticals, Inc. Class A Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap moved from $4.39 Billion to $ 6.24 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.24 Billion | +42.14% |
| 2025 | $4.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Amneal Pharmaceuticals, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.96 Billion USD |
| MoneyControl | $5.96 Billion USD |
| MarketWatch | $5.96 Billion USD |
| marketcap.company | $5.96 Billion USD |
| Reuters | $5.96 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more